Human safety and pharmacokinetics study of orally administered icariin: Randomized, double-blind, placebo-controlled trial

Edson S Brown, Collette Bice, William C. Putnam, Richard Leff, Alexandra Kulikova, Alyson K Nakamura, Elena Ivleva, Erin A Van Enkevort, Traci Holmes, Nyokabi Miingi

Research output: Contribution to journalArticle

Abstract

Preclinical literature suggests that icariin, a flavonoid found in Epimedium, may have potential for medical and psychiatric conditions. The objective of this study was to examine the safety, tolerability, and pharmacokinetics of orally administered icariin at doses of 100 to 1,680 mg/day in 24 healthy adult participants. Cognition, mood, and side effects were assessed over 5 days. Multiple blood samples were obtained over 24 hours to assess bioavailability and pharmacokinetics. Data were analyzed using a Wilcoxon signed rank test and Mann-Whitney U test. At all doses, either very low or undetectable blood levels of icariin were observed, demonstrating the low bioavailability of the oral formulation and preventing a determination of pharmacokinetic properties. No significant between-group differences were observed on side effect scales, either by self-report, or on cognitive assessments. A statistically significant, but not clinically significant, increase in self-reported depressive symptom severity was observed with icariin relative to placebo. Tolerability of icariin was good except at the highest dose. Two participants receiving 1,680 mg of icariin discontinued the study drug due to gastrointestinal symptoms. Bioavailability of oral icariin appears to be low at all doses tested. Although icariin appears generally to have a favorable tolerability profile, the highest doses may be associated with gastrointestinal distress. Different drug formulation and delivery method may be needed to assess the pharmacokinetic profile of icariin adequately.

Original languageEnglish (US)
JournalNatural Product Communications
Volume14
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

pharmacokinetics
placebos
Pharmacokinetics
Placebos
Safety
Biological Availability
bioavailability
dosage
Nonparametric Statistics
signs and symptoms (animals and humans)
mouth
Epimedium
adverse effects
drug formulations
icariin
Drug Compounding
blood
emotions
distress
Flavonoids

Keywords

  • Bioavailability
  • Icariin
  • Pharmacokinetics
  • Safety

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Plant Science
  • Complementary and alternative medicine

Cite this

Human safety and pharmacokinetics study of orally administered icariin : Randomized, double-blind, placebo-controlled trial. / Brown, Edson S; Bice, Collette; Putnam, William C.; Leff, Richard; Kulikova, Alexandra; Nakamura, Alyson K; Ivleva, Elena; Van Enkevort, Erin A; Holmes, Traci; Miingi, Nyokabi.

In: Natural Product Communications, Vol. 14, No. 6, 01.01.2019.

Research output: Contribution to journalArticle

Brown, Edson S ; Bice, Collette ; Putnam, William C. ; Leff, Richard ; Kulikova, Alexandra ; Nakamura, Alyson K ; Ivleva, Elena ; Van Enkevort, Erin A ; Holmes, Traci ; Miingi, Nyokabi. / Human safety and pharmacokinetics study of orally administered icariin : Randomized, double-blind, placebo-controlled trial. In: Natural Product Communications. 2019 ; Vol. 14, No. 6.
@article{8520778221aa49fca3dd5b6a434aeebc,
title = "Human safety and pharmacokinetics study of orally administered icariin: Randomized, double-blind, placebo-controlled trial",
abstract = "Preclinical literature suggests that icariin, a flavonoid found in Epimedium, may have potential for medical and psychiatric conditions. The objective of this study was to examine the safety, tolerability, and pharmacokinetics of orally administered icariin at doses of 100 to 1,680 mg/day in 24 healthy adult participants. Cognition, mood, and side effects were assessed over 5 days. Multiple blood samples were obtained over 24 hours to assess bioavailability and pharmacokinetics. Data were analyzed using a Wilcoxon signed rank test and Mann-Whitney U test. At all doses, either very low or undetectable blood levels of icariin were observed, demonstrating the low bioavailability of the oral formulation and preventing a determination of pharmacokinetic properties. No significant between-group differences were observed on side effect scales, either by self-report, or on cognitive assessments. A statistically significant, but not clinically significant, increase in self-reported depressive symptom severity was observed with icariin relative to placebo. Tolerability of icariin was good except at the highest dose. Two participants receiving 1,680 mg of icariin discontinued the study drug due to gastrointestinal symptoms. Bioavailability of oral icariin appears to be low at all doses tested. Although icariin appears generally to have a favorable tolerability profile, the highest doses may be associated with gastrointestinal distress. Different drug formulation and delivery method may be needed to assess the pharmacokinetic profile of icariin adequately.",
keywords = "Bioavailability, Icariin, Pharmacokinetics, Safety",
author = "Brown, {Edson S} and Collette Bice and Putnam, {William C.} and Richard Leff and Alexandra Kulikova and Nakamura, {Alyson K} and Elena Ivleva and {Van Enkevort}, {Erin A} and Traci Holmes and Nyokabi Miingi",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1934578X19856789",
language = "English (US)",
volume = "14",
journal = "Natural Product Communications",
issn = "1934-578X",
publisher = "Natural Product Communications",
number = "6",

}

TY - JOUR

T1 - Human safety and pharmacokinetics study of orally administered icariin

T2 - Randomized, double-blind, placebo-controlled trial

AU - Brown, Edson S

AU - Bice, Collette

AU - Putnam, William C.

AU - Leff, Richard

AU - Kulikova, Alexandra

AU - Nakamura, Alyson K

AU - Ivleva, Elena

AU - Van Enkevort, Erin A

AU - Holmes, Traci

AU - Miingi, Nyokabi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Preclinical literature suggests that icariin, a flavonoid found in Epimedium, may have potential for medical and psychiatric conditions. The objective of this study was to examine the safety, tolerability, and pharmacokinetics of orally administered icariin at doses of 100 to 1,680 mg/day in 24 healthy adult participants. Cognition, mood, and side effects were assessed over 5 days. Multiple blood samples were obtained over 24 hours to assess bioavailability and pharmacokinetics. Data were analyzed using a Wilcoxon signed rank test and Mann-Whitney U test. At all doses, either very low or undetectable blood levels of icariin were observed, demonstrating the low bioavailability of the oral formulation and preventing a determination of pharmacokinetic properties. No significant between-group differences were observed on side effect scales, either by self-report, or on cognitive assessments. A statistically significant, but not clinically significant, increase in self-reported depressive symptom severity was observed with icariin relative to placebo. Tolerability of icariin was good except at the highest dose. Two participants receiving 1,680 mg of icariin discontinued the study drug due to gastrointestinal symptoms. Bioavailability of oral icariin appears to be low at all doses tested. Although icariin appears generally to have a favorable tolerability profile, the highest doses may be associated with gastrointestinal distress. Different drug formulation and delivery method may be needed to assess the pharmacokinetic profile of icariin adequately.

AB - Preclinical literature suggests that icariin, a flavonoid found in Epimedium, may have potential for medical and psychiatric conditions. The objective of this study was to examine the safety, tolerability, and pharmacokinetics of orally administered icariin at doses of 100 to 1,680 mg/day in 24 healthy adult participants. Cognition, mood, and side effects were assessed over 5 days. Multiple blood samples were obtained over 24 hours to assess bioavailability and pharmacokinetics. Data were analyzed using a Wilcoxon signed rank test and Mann-Whitney U test. At all doses, either very low or undetectable blood levels of icariin were observed, demonstrating the low bioavailability of the oral formulation and preventing a determination of pharmacokinetic properties. No significant between-group differences were observed on side effect scales, either by self-report, or on cognitive assessments. A statistically significant, but not clinically significant, increase in self-reported depressive symptom severity was observed with icariin relative to placebo. Tolerability of icariin was good except at the highest dose. Two participants receiving 1,680 mg of icariin discontinued the study drug due to gastrointestinal symptoms. Bioavailability of oral icariin appears to be low at all doses tested. Although icariin appears generally to have a favorable tolerability profile, the highest doses may be associated with gastrointestinal distress. Different drug formulation and delivery method may be needed to assess the pharmacokinetic profile of icariin adequately.

KW - Bioavailability

KW - Icariin

KW - Pharmacokinetics

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85068669945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068669945&partnerID=8YFLogxK

U2 - 10.1177/1934578X19856789

DO - 10.1177/1934578X19856789

M3 - Article

AN - SCOPUS:85068669945

VL - 14

JO - Natural Product Communications

JF - Natural Product Communications

SN - 1934-578X

IS - 6

ER -